Skip to main content

Table 1 Baseline characteristics and clinical manifestations of the COVID-19 among studied participants according to the severity of disease

From: The correlation between serum selenium, zinc, and COVID-19 severity: an observational study

  COVID-19 disease severity P value
Mild
n = 38
(45.2%)
Moderate
n = 27
(32.1%)
Severe
n = 19
(22.6%)
Gender     
 Number (%) of women 15 (39.5%) 15 (55.6%) 7 (36.8%)  
 Number (%) of men 23 (60.5%) 12 (44.4%) 12 (63.2%) 0.372
Age (year)a
(mean, standard deviation)
51 ± 14 59 ± 14 81 ± 7  < 0.001
Having a history of chronic
HTN, diabetes, CVDs or COPD
18 (50.0%) 19 (70.4%) 15 (78.9%) 0.07
Having history of neurological disease 10 (27.8%) 12 (44.4%) 6 (31.6%) 0.372
Delusion 1 (3.1%) 1 (3.7%) 1 (5.3%) 0.928
Dizziness 4 (12.5%) 5 (18.5%) 1 (5.3%) 0.415
Headache 7 (21.9%) 8 (29.6%) 2 (10.5%) 0.303
Vertigo 4 (12.5%) 4 (14.8%) 0 (0.0%) 0.228
Seizure 4 (12.5%) 1 (3.7%) 3 (15.8%) 0.356
Fever 20 (62.5%) 22 (81.5%) 10 (52.6%) 0.100
Mechanical ventilation 10 (29.4%) 10 (37.0%) 12 (63.2%) 0.051
Myalgia 11 (28.9%) 3 (11.1%) 3 (15.8%) 0.109
Respiratory symptoms 25 (65.8%) 17 (63%) 15 (78.9%) 0.771
Loss of appetite 9 (23.7%) 10 (37%) 2 (10.5%) 0.078
Fatigue 7 (18.4%) 9 (33.3%) 8 (42.1%) 0.255
Vomiting 8 (21.7%) 5 (18.5%) 3 (15.8%) 0.738
Constipation 1 (2.8%) 0 (0%) 1 (5.3%) 0.555
Diarrhea 3 (7.9%) 2 (7.4%) 2 (10.5%) 0.970
Other GI Symptomsb 5 (13.2%) 3 (11.1%) 1 (5.3%) 0.543
Dysphagia 0 (0%) 1 (3.7%) 1 (5.3%) 0.454
  1. aData are presented as mean (standard deviation)
  2. bOther GI symptoms include: reflux, stomachache, and stomach tenderness